1. Introduction

Decentralized Genome Governance refers to a legal, institutional, and regulatory framework in which authority over genomic information, genetic research, genome-editing technologies, biological databases, and genetic resources is distributed among multiple institutions rather than concentrated in a single central government authority.

Genome governance concerns the collection, storage, analysis, sharing, ownership, protection, and commercial use of genetic information. Decentralization introduces multiple levels of decision-making, including:

National governments and regulatory authorities.

State and regional governments.

Universities and research institutions.

Hospitals and healthcare organizations.

Indigenous and local communities.

Independent ethics committees.

International scientific and regulatory organizations.

Individuals who provide genetic samples or genomic information.

The central objective is to balance scientific innovation with individual autonomy, genetic privacy, public health, research accountability, equitable benefit-sharing, and protection against genetic discrimination.

For example, a university may maintain a genomic database, a hospital may collect patient DNA samples, an independent ethics committee may approve the research, and a national regulator may supervise the clinical application of the resulting technology. This creates a decentralized governance structure in which different institutions exercise different responsibilities.

Importantly, decentralization does not mean the absence of national regulation. It means distributing regulatory functions while maintaining common legal standards, accountability, and effective oversight.

2. Meaning and Conceptual Foundations

Decentralized genome governance is based on the principle that genomic information is too complex and socially significant to be governed exclusively through a single administrative authority.

Genomic data can reveal information about an individual, their biological relatives, ancestry, inherited disease risks, and potentially identifiable characteristics. Consequently, governance must address both individual rights and collective interests.

Its principal foundations include:

A. Institutional decentralization: Different institutions receive authority over genomic research, data management, ethical approval, and clinical applications.

B. Data decentralization: Genomic information may remain within separate hospitals, laboratories, universities, or regional databases instead of being transferred into one centralized repository.

C. Community participation: Indigenous communities and populations contributing genetic resources participate in decisions about collection, research, access, and benefit-sharing.

D. Regulatory pluralism: Multiple legal authorities and ethical institutions regulate different aspects of genomic activities.

E. Distributed accountability: Researchers, laboratories, hospitals, database operators, commercial biotechnology companies, and regulators have distinct responsibilities.

3. Major Principles of Decentralized Genome Governance

A. Genetic Privacy and Individual Autonomy

Genetic information is particularly sensitive because it can disclose inherited characteristics, predispositions to diseases, family relationships, and biological ancestry.

Decentralized governance must ensure that every participating institution protects genetic information against unauthorized access, disclosure, commercial exploitation, and discriminatory use.

The main legal requirements include:

Informed and voluntary consent.

Purpose limitation in genetic-data processing.

Confidentiality and secure storage.

Appropriate access controls.

Transparency regarding secondary research.

Procedures for withdrawal of consent where legally applicable.

Protection of relatives and identifiable population groups.

The principle of individual autonomy requires that genetic samples collected for one medical purpose should not automatically become available for unrelated research.

B. Institutional Accountability

Decentralized genome governance creates multiple institutional responsibilities.

For example:

A major legal challenge arises when misconduct occurs across several institutions. Each institution may attempt to shift responsibility to another.

Therefore, a sound governance system requires clearly defined duties, contractual responsibility, audit trails, and mechanisms for resolving disputes.

C. Community and Indigenous Genetic Sovereignty

Genetic information is not always merely an individual matter. Research involving a particular indigenous or geographically concentrated population may reveal information about the entire community.

For example, genomic research may identify:

Population ancestry.

Inherited disease patterns.

Genetic relationships.

Population-specific biological characteristics.

Historically significant genetic information.

Communities may therefore demand consultation, restrictions on research, control over access, and equitable sharing of benefits.

The principle of Indigenous Data Sovereignty recognizes the interests of Indigenous peoples in governing information concerning their communities.

However, collective governance must not automatically replace the individual consent rights of research participants.

D. Federated and Distributed Genomic Databases

One important technological model is federated genomic governance.

Under this arrangement, different hospitals and research institutions retain genomic information in their respective secure environments. Researchers send approved analytical instructions to those institutions instead of necessarily transferring all genomic information to one central database.

Frontiers | Federated, governed, and interoperable? The emerging architecture of public human genomic data infrastructures: a European perspective

frontiersin.org

For example:

Hospital A stores genomic information locally.

University B stores another genomic dataset.

Research Institute C seeks to conduct a joint study.

Approved analytical software processes the information within each institution.

Only permitted results are shared with the research institute.

This model can reduce unnecessary transfers of identifiable genetic information.

However, federated systems do not automatically guarantee privacy. Data leakage, re-identification, unauthorized queries, and security vulnerabilities may still occur.

A detailed legal and technical analysis of this model is provided in Federated Analysis for Privacy-Preserving Data Sharing: A Technical and Legal Primer (2023).

Annual Reviews+1

E. Decentralized Ethical Review

Traditional research governance often relies on a central ethics committee or national regulatory authority.

Decentralized governance permits institutional ethics committees to evaluate research according to local circumstances, scientific risks, participant characteristics, and community concerns.

However, decentralization creates a danger of inconsistent ethical standards.

For example, one institution may approve a genome-editing experiment while another institution may reject an equivalent experiment because of different interpretations of research risks.

A common minimum ethical standard is therefore essential.

4. Legal Framework Governing Decentralized Genome Governance

A. International Legal Framework

1. UNESCO Universal Declaration on the Human Genome and Human Rights, 1997

The Declaration recognizes the importance of protecting human dignity and fundamental rights in the application of genetic science.

It establishes principles concerning human dignity, non-discrimination, genetic research, and the protection of human beings against improper applications of genomic technologies.

It also provides an important normative foundation for preventing the treatment of the human genome as an unrestricted commercial resource.

Source: UNESCO Declaration on the Human Genome and Human Rights.

2. UNESCO International Declaration on Human Genetic Data, 2003

This Declaration is particularly important for decentralized genomic databases.

It addresses:

Collection of genetic samples.

Processing of genetic information.

Informed consent.

Privacy and confidentiality.

Access to genetic information.

International cooperation.

Genetic-data use in medical and scientific research.

Its Article 2 defines consent in terms of freely given, specific, informed, and express agreement.

Article 14 addresses privacy and confidentiality.

It therefore provides a useful framework for regulating multiple institutions that collect and exchange genomic information.

Source: UNESCO International Declaration on Human Genetic Data.

3. World Health Organization Framework on Human Genome Editing, 2021

The WHO framework recognizes that human genome editing requires oversight at institutional, national, regional, and international levels.

It addresses somatic and germline genome editing, ethical oversight, scientific responsibility, regulatory coordination, and governance gaps.

It is particularly relevant because decentralized institutions may independently undertake genome-editing research without sufficient coordination.

The framework supports coordinated oversight rather than isolated institutional decision-making.

Source: WHO Human Genome Editing: A Framework for Governance.

B. Indian Legal Framework

India's decentralized genome governance must be understood through constitutional rights, data-protection law, biomedical research standards, and biotechnology regulation.

1. Article 21 of the Constitution of India

Article 21 protects life and personal liberty. Its interpretation encompasses privacy, dignity, bodily autonomy, and personal autonomy.

These principles are relevant to:

Collection of DNA samples.

Genetic testing without proper authorization.

Unauthorized genomic-data sharing.

Genetic profiling.

Genetic discrimination.

Compulsory genetic testing.

2. Digital Personal Data Protection Act, 2023

The DPDP Act establishes a framework for processing digital personal data.

Genomic information capable of identifying an individual can fall within the concept of personal data.

The Act is relevant to hospitals, laboratories, genomic databases, biotechnology companies, and other organizations processing such information.

An important transitional point is that, as of 5 November 2026, the Act's core processing and individual-rights provisions have not yet commenced. The commencement notification schedules those provisions for 14 May 2027. The Digital Personal Data Protection Rules, 2025 were notified with a phased commencement schedule as well.

MeitY+2

3. Information Technology Act, 2000

Section 43A and the Information Technology (Reasonable Security Practices and Procedures and Sensitive Personal Data or Information) Rules, 2011 have historically provided an important framework for protecting sensitive personal information handled by covered bodies corporate.

Health and biometric information may be relevant when genomic information is processed in connection with medical or biological identification systems.

4. Indian Council of Medical Research Guidelines

The ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017 provide important ethical standards for genomic research.

They address:

Informed consent.

Protection of vulnerable participants.

Biological sample collection.

Research ethics committees.

Confidentiality.

Biobanking.

Secondary use of biological samples and data.

Benefit-sharing and community interests.

5. Biological Diversity Act, 2002

The Biological Diversity Act is relevant where research involves biological resources and associated traditional knowledge falling within its scope.

It provides a framework for access regulation and benefit-sharing, particularly in relation to biological resources and associated knowledge.

It should not, however, be confused with a comprehensive law governing all human genomic information.

6. DNA Technology (Use and Application) Regulation Bill, 2019

The proposed legislation sought to establish a framework for regulating DNA technology in civil and criminal proceedings, including DNA laboratories and DNA data banks.

The Bill should not be treated as an operative comprehensive DNA-regulation statute. It did not become an enacted law.

5. Important Case Laws on Decentralized Genome Governance

Although courts have not developed a single comprehensive doctrine called Decentralized Genome Governance, several important decisions establish the legal principles upon which such governance can be built.

Case 1. Justice K.S. Puttaswamy v. Union of India (2017)

Indian Supreme Court

Citation: (2017) 10 SCC 1.

Facts and background:

The case concerned whether the right to privacy is protected as a fundamental right under the Indian Constitution.

A nine-judge Constitution Bench of the Supreme Court unanimously recognized privacy as a fundamental right.

Judgment and legal principles:

The Court recognized that privacy includes personal autonomy, bodily integrity, informational privacy, and the ability to control important aspects of personal information.

It also established that state interference with privacy must satisfy three essential requirements:

Legality: There must be a valid legal basis.

Legitimate aim: The interference must pursue a legitimate governmental objective.

Proportionality: The measure must be proportionate to its objective.

Relevance to decentralized genome governance:

This decision is highly relevant to genetic databases and genomic research.

For example, if a government institution, university, or hospital collects genomic information without adequate legal justification, the collection may raise constitutional privacy concerns.

Similarly, decentralized institutions cannot escape privacy obligations merely because they operate independently.

Legal significance: Puttaswamy provides a constitutional foundation for genetic privacy, individual autonomy, and accountability in genomic-data processing.

Source: Read the Puttaswamy judgment.

Case 2. Havasupai Tribe v. Arizona Board of Regents (2008)

United States Court of Appeals

Citation: 906 P.2d 478?

The relevant reported appellate decision is 220 Ariz. 214, 204 P.3d 1063? The 2008 Arizona Court of Appeals decision concerned the Havasupai Tribe litigation.

Facts:

Members of the Havasupai Tribe provided blood samples for research into type 2 diabetes.

Subsequently, the samples were allegedly used for additional research, including studies concerning schizophrenia, migration, and population ancestry, beyond the original purposes understood by participants.

The dispute raised questions about informed consent, institutional responsibility, cultural privacy, and secondary use of genetic material.

Judgment:

The Arizona Court of Appeals reversed and remanded the lower-court judgments concerning the sufficiency of the Tribe's notice of claim.

The decision did not finally determine every allegation of misuse on its merits.

The litigation later resulted in a settlement in 2010.

Relevance to decentralized genome governance:

This case demonstrates why individual universities and laboratories need strong research oversight.

It highlights several governance requirements:

Consent must clearly explain the intended research.

Secondary use must receive appropriate authorization.

Institutions must respect community interests.

Researchers must maintain accountability for samples.

Genetic research must not disregard cultural and religious concerns.

Legal significance: The Havasupai litigation is an important example of the risks arising when research institutions exercise control over genetic materials without adequately respecting participants' expectations and community interests.

Sources: Read the Havasupai appellate judgment and Research governance and Indigenous genomic sovereignty.

Case 3. Moore v. Regents of the University of California (1990)

California Supreme Court

Citation: 51 Cal. 3d 120, 793 P.2d 479 (1990).

Facts:

John Moore underwent treatment for hairy-cell leukemia. His physician obtained biological samples from him but did not adequately disclose the physician's research and financial interests in those samples.

The samples were subsequently used to develop a commercially valuable cell line.

Moore brought legal proceedings alleging, among other things, breach of fiduciary duty, lack of informed consent, and conversion.

Judgment:

The California Supreme Court held that the allegations could support claims for breach of fiduciary duty and lack of informed consent.

However, it rejected the conversion claim based on ownership of the removed cells.

Relevance to decentralized genome governance:

The decision establishes an important distinction between:

Physical ownership of biological material.

Rights to informed consent.

Disclosure of research interests.

Commercial exploitation of biological samples.

A university or biotechnology company cannot assume that receiving a biological sample automatically authorizes every subsequent research or commercial use.

Legal significance: The case supports transparency, informed consent, and institutional accountability in genomic research and biotechnology commercialization.

Source: Read Moore v. Regents.

Case 4. Greenberg v. Miami Children's Hospital Research Institute (2003)

United States District Court

Citation: 264 F. Supp. 2d 1064 (S.D. Fla. 2003).

Facts:

Parents of children suffering from Canavan disease and supporting organizations contributed biological materials, research assistance, and information to facilitate genetic research.

The research resulted in the identification and patenting of the relevant gene sequence and development of genetic screening tests.

A dispute arose concerning the researcher's intellectual-property interests and the expectations of those who had contributed to the research.

Judgment:

The court considered claims involving informed consent, fiduciary obligations, unjust enrichment, and the commercialization of genetic discoveries.

The plaintiffs' claims concerning a proprietary interest in the genetic discovery were not accepted as a general ownership entitlement merely because they had contributed to the research.

Relevance to decentralized genome governance:

The case demonstrates the importance of establishing clear rules concerning:

Contributions of genetic materials.

Research agreements.

Intellectual-property rights.

Commercialization of genomic discoveries.

Benefit-sharing arrangements.

Legal significance: Decentralized genomic research requires transparent agreements between donors, research institutions, universities, and commercial biotechnology organizations.

Source: Read the Greenberg case summary.

Case 5. Samira Kohli v. Dr. Prabha Manchanda (2008)

Indian Supreme Court

Citation: (2008) 2 SCC 1.

Facts:

The dispute concerned medical treatment and the extent of consent given by a patient for a medical procedure.

The patient had consented to a diagnostic procedure, but the doctor also performed an additional surgical procedure.

Judgment:

The Supreme Court explained the requirements of valid informed consent and distinguished consent to a diagnostic procedure from consent to additional treatment.

Consent must be genuine, voluntary, and sufficiently informed, subject to recognized emergency exceptions.

Relevance to decentralized genome governance:

The case is relevant where genomic research involves additional procedures or uses beyond the original consent.

For example, consent to genetic testing for a particular inherited condition should not automatically be treated as unrestricted consent to unrelated commercial research.

The case supports the need for clear and specific consent procedures at hospitals, laboratories, and research institutions.

Legal significance: It strengthens the legal foundation for informed consent in genetic testing, genomic research, and biotechnology-related medical procedures.

Case 6. S and Marper v. United Kingdom (2008)

European Court of Human Rights

Citation: Applications Nos. 30562/04 and 30566/04, Grand Chamber, 4 December 2008.

Facts:

The applicants challenged the indefinite retention of their fingerprints, cellular samples, and DNA profiles by the police despite the fact that they had not been convicted of criminal offences.

Judgment:

The European Court of Human Rights found that the blanket and indiscriminate retention of the applicants' biological samples and DNA profiles violated Article 8 of the European Convention on Human Rights, concerning respect for private and family life.

Relevance to decentralized genome governance:

The case demonstrates that genetic databases require:

Clear retention periods.

Defined purposes.

Appropriate access restrictions.

Review and deletion mechanisms.

Independent oversight.

The decision is especially relevant to forensic DNA databases operated by different police agencies and public authorities.

Legal significance: Decentralized genomic databases cannot justify unlimited retention merely because genetic information may be useful for future investigations.

6. Major Legal Challenges in Decentralized Genome Governance

A. Fragmentation of Regulatory Authority

Different institutions may apply different ethical standards and data-protection procedures.

For example, one hospital may impose strict consent requirements, while another research institution may permit broader secondary research.

This can produce inconsistent regulatory outcomes.

Legal solution: Establish national minimum standards, common consent requirements, independent audits, and coordinated regulatory supervision.

B. Cross-Institutional Genetic Data Leakage

Genomic information may move between hospitals, universities, laboratories, cloud-storage providers, and international research partners.

Every transfer creates potential privacy and security risks.

Legal solution: Introduce data-sharing agreements, encryption, role-based access controls, security audits, and clear liability for unauthorized disclosure.

C. Disputes Regarding Ownership of Genetic Information

Genetic governance raises difficult questions:

Does an individual own their DNA sample?

Does a hospital own the stored biological material?

Can a university commercialize discoveries based on donated samples?

Do communities have rights over population-level genetic information?

The law does not provide one universal answer to all these questions.

Ownership of physical samples, privacy rights over personal information, contractual rights, and intellectual-property rights must be considered separately.

The reasoning in Moore and Greenberg illustrates these distinctions.

D. Lack of Community Participation

Research involving indigenous or vulnerable populations may create exploitation risks.

If communities are excluded from research decisions, they may lose control over how their genetic resources and associated knowledge are used.

Legal solution: Provide meaningful community consultation, culturally appropriate consent, transparent benefit-sharing, and mechanisms for addressing community objections.

E. Liability for Genetic Research Misconduct

Decentralization may create confusion about who is responsible when genomic research causes harm.

Potentially responsible parties include:

Principal investigators.

Research institutions.

Laboratory operators.

Hospitals.

Biotechnology companies.

Data custodians.

Ethics committees, where their own legally recognized duties have been breached.

Liability should depend on the particular party's duties, conduct, contractual obligations, and applicable law.

F. Regulatory Competition

Different jurisdictions may adopt different standards for genome editing, genetic testing, data storage, and biotechnology commercialization.

Researchers may move projects to jurisdictions with less restrictive oversight.

This creates regulatory arbitrage.

Legal solution: International cooperation, common minimum standards, mutual regulatory assistance, and transparent cross-border research agreements.

7. Decentralized Genome Governance and Artificial Intelligence

Artificial intelligence increasingly influences genomic research.

AI systems can analyze large genetic datasets, predict disease risks, identify mutations, and support personalized medicine.

Decentralized governance creates additional legal questions.

1. Algorithmic accountability: Which institution is responsible when an AI genomic system produces an incorrect diagnosis?

2. Data ownership: Who controls genomic information used to train AI systems?

3. Algorithmic discrimination: Can genetic predictions be used unfairly in employment, insurance, or healthcare?

4. Automated research authorization: Can an AI system independently approve access to genomic databases?

5. Transparency: Must institutions explain how AI algorithms process genetic information?

A suitable governance framework should require human oversight for high-impact decisions, algorithmic auditing, documented authorization, and clear allocation of institutional responsibility.

8. Suggested Model for Effective Decentralized Genome Governance

A legally accountable system should combine institutional independence with common national standards.

Proposed governance architecture

National legal and regulatory framework

Common privacy, safety, research and accountability standards

Institutional governance

Universities, hospitals and laboratories

Independent oversight

Ethics committees and auditors

Community participation

Indigenous and local communities

Individual rights

Consent, privacy and autonomy

Secure genomic-data ecosystem

Distributed databases, controlled access, federated analysis and audit trails

The proposed model should incorporate the following safeguards:

A common national genomic governance policy.

Independent institutional ethics committees.

Legally valid informed-consent procedures.

Secure and interoperable genomic databases.

Community consultation and benefit-sharing.

Transparent commercial research agreements.

Independent cybersecurity and privacy audits.

Cross-border data-sharing safeguards.

Clear institutional liability.

Accessible complaint and dispute-resolution mechanisms.

9. Future Developments in Decentralized Genome Governance

Several developments are likely to influence the future legal framework.

A. Blockchain-Based Genomic Governance

Blockchain may help maintain records of consent, data access, research authorization, and transfers of genomic information. However, immutable records must be designed carefully to avoid permanently exposing personal information.

B. Federated Genomic Research

Federated research networks may enable universities and hospitals to collaborate without routinely transferring complete genomic datasets.

C. Genetic Data Sovereignty

Individuals and communities may demand stronger rights concerning access, use, sharing, and commercialization of genetic information.

D. International Regulatory Harmonization

International organizations may increasingly develop common standards for genome editing, genomic databases, research ethics, and cross-border genetic-data transfers.

E. Stronger Liability Frameworks

Future legislation may establish more specific liability rules for unauthorized genomic-data use, research misconduct, genetic discrimination, and unsafe genome-editing practices.

10. Critical Analysis

Decentralized genome governance offers significant advantages because it distributes decision-making, encourages institutional participation, supports scientific collaboration, and allows communities to participate in genomic research.

However, decentralization also creates serious legal difficulties.

First, multiple institutions may apply inconsistent ethical standards. Second, genetic information may be transferred without sufficient authorization. Third, institutional fragmentation can make it difficult to identify the responsible party when harm occurs. Fourth, commercial research may create conflicts between public scientific interests and private financial interests.

The Havasupai litigation demonstrates the importance of respecting participant consent and community interests. Puttaswamy establishes constitutional privacy principles in India, while Moore emphasizes disclosure of research interests and informed consent.

Therefore, decentralized governance should not mean unrestricted institutional independence. It should operate within a legally enforceable system of shared responsibility, independent oversight, individual rights, and common regulatory standards.

11. Conclusion

Decentralized Genome Governance represents an important development in modern biotechnology law. It recognizes that genomic information is simultaneously a scientific resource, a form of personal information, and a source of collective social and ethical concerns.

Its effectiveness depends on balancing institutional autonomy with legal accountability.

The principles established in Justice K.S. Puttaswamy v. Union of India, Havasupai Tribe v. Arizona Board of Regents, Moore v. Regents of the University of California, Greenberg v. Miami Children's Hospital, Samira Kohli v. Dr. Prabha Manchanda, and S and Marper v. United Kingdom provide important foundations for this emerging field.

Ultimately, a successful decentralized genomic governance system must ensure that scientific institutions can innovate without compromising privacy, dignity, informed consent, community interests, and human rights.

12. Important Case Law Reference Table

Important research qualification: These cases do not establish a single judicial doctrine formally named decentralized genome governance. They provide related legal principles from which the doctrine can be developed. The Havasupai appellate decision is Havasupai Tribe v. Arizona Board of Regents, No. 1 CA-CV 07-0454 (Ariz. Ct. App. Nov. 28, 2008); its appellate ruling concerned procedural notice-of-claim issues, not a final determination of every allegation on the merits.

13. Further Reading and Legal Sources

WHO – Human Genome Editing: A Framework for Governance (2021).

UNESCO – International Declaration on Human Genetic Data (2003).

Supreme Court of India – Puttaswamy judgment (2017).

Moore v. Regents (1990).

Havasupai Tribe v. Arizona Board of Regents (2008).

Greenberg v. Miami Children's Hospital (2003).

This explanation is an academic legal analysis. The applicability of individual statutes and judgments depends on the jurisdiction and facts of the particular genomic research activity.